摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-amino-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione

中文名称
——
中文别名
——
英文名称
6-amino-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione
英文别名
6-imino-1H-imidazo[4,5-e][1,3]diazepine-4,8-dione;6-amino-3,7-dihydroimidazo[4,5-e][1,3]diazepine-4,8-dione
6-amino-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione化学式
CAS
——
化学式
C6H5N5O2
mdl
——
分子量
179.138
InChiKey
OBUMKYUZIHSFTQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.2
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    113
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    参考文献:
    名称:
    环扩增(“脂肪”)核苷和核苷酸类似物对黄病毒NTPase / Helase(包括西尼罗河病毒,丙型肝炎病毒和日本脑炎病毒)表现出强大的体外活性。
    摘要:
    一系列含有咪唑并[4,5-e] [1,3]二氮杂ring环系统的环膨胀(“脂肪”)杂环,核苷和核苷酸类似物(REN)(9、14、15、18、24-26 ,28、31和33)和咪唑并[4,5-e] [1,2,4]三氮杂ring环系统(30b,30c,32和34)已被合成为黄病毒科NTPase /螺旋酶的潜在抑制剂包括西尼罗河病毒(WNV),丙型肝炎病毒(HCV)和日本脑炎病毒(JEV)。该研究还包括人酶Suv3(delta1-159)的氨基末端截短形式,以评估RENs对病毒酶的选择性。REN的类似物包括杂环碱基第1位的结构变异,并且在两种糖部分的类型(核糖,2'-脱氧核糖,和无环糖)以及这些糖与杂环碱基的连接方式(α与β端基异构构型)。针对病毒NTPase / helase的解旋酶和ATPase活性分别进行生化筛选目标REN。许多REN抑制病毒解旋酶活性,其IC50值在微摩尔浓度范围内变化,
    DOI:
    10.1021/jm030842j
点击查看最新优质反应信息

文献信息

  • Ring expanded nucleosides and nucleotides
    申请人:——
    公开号:US20040077564A1
    公开(公告)日:2004-04-22
    The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded (“fat”) heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS), hepatitis, Epstein-Barr and cytomegalovirus.
    本发明涉及含有环扩张(“肥胖”)杂环环代替嘌呤嘌呤核苷类似物和未经改性或改性的糖残基的组合物,以及这些组合物的药学上可接受的衍生物,以及其使用方法。特别地,这些组合物可用于治疗某些癌症、细菌、真菌、寄生虫和病毒感染,包括但不限于获得性免疫缺陷综合症(AIDS)、肝炎、EB病毒和巨细胞病毒。
  • Ring-expanded nucleosides and nucleotides
    申请人:Nabi
    公开号:EP1227103B1
    公开(公告)日:2006-07-26
  • RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES
    申请人:Nabi
    公开号:EP0724587B1
    公开(公告)日:2002-09-04
  • US6677310B1
    申请人:——
    公开号:US6677310B1
    公开(公告)日:2004-01-13
查看更多

同类化合物

脱氧助间型霉素 叔-丁基3-溴-8,9-二氢-5H-咪唑并[1,2-D][1,4]二氮杂卓-7(6H)-甲酸基酯 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 9H-imidazo[2,1-i]purin-8-one 3-(2-chlorobenzyl)-7-(4-methoxybenzyl)-3,7-dihydro-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one R-(-)-7-Methyl-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidin-5-on benzyl N-[(23R,52R)-52-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,64-icosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-23-yl]carbamate tert-butyl (1-(1-(but-2-yn-1-yl)-4-methyl-7-oxo-6,7-dihydro-1H-imidazo[4,5-d]pyridazin-2-yl)piperidin-3-yl)carbamate 14-(7-(bromomethyl)-1H-imidazo[4,5-c]pyridin-4-yl)-14-azadispiro[5.0.57.36]pentadecane-13,15-dione cyclo-(-ImPyPyPy-(R)β-NHCbzγ-ImPyPyPy-(R)β-NHCbzγ-) benzyl N-[(23R,52R)-23-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,61,64-henicosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-52-yl]carbamate 2-tert-butyldimethylsilyl-5-[(1S,2S)-2-dibenzylamino-1,4-dihydroxybutyl]-N,N-dimethylimidazole-1-sulfonamide 4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile benzyl N-[(23R,52R)-52-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,61,64-henicosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-23-yl]carbamate (8R)-3-(p-Methoxybenzyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 8H-Pyrazino[1,2-a]pyrimidine-8-carboxylic acid, 2-(2-aminoethyl)-4,6,7,9-tetrahydro-4-oxo-, 1,1-dimethylethyl ester 3,4,6,7-Tetrahydro-7-methyl-4-propylimidazo[4,5-e][1,4]diazepine-5,8-dione 1-methyl-1,2,3,4-tetrahydropyrido<3',2':4,5>imidazo<1,2-a>pyrimidin-2-one 5-(4H-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine hydrobromide tert-butyl 7-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-3,4-dihydropyrido[4',3':4,5]imidazo[1,2-a]pyridine-2(1H)-carboxylate N-(7H-Imidazo<1,5c><1,3>diazepin-5(6H)-yliden)-N'-<2-<(5-methyl-1H-imidazol-4-yl)methylthio>ethyl>harnstoff 1,2-Dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-e][1,4]diazepin-8-one 1-benzyl-5-hydroxy-4,5,6,7-tetrahydroimidazo<4,5-e><1,4>diazepin-8(1H)-one [5-(8-Hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-pentyl]-phosphonic acid dibenzyl ester 6,7-dihydro-3-<(2-hydroxyethoxy)methyl>imidazo<4,5-d><1,3>diazepin-8(3H)-one 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid monohydrochloride 1,6-dimethyl-1,4,6,7-tetrahydro-imidazo[4,5-b]pyridin-5-one 1-Benzyl-7,8-dihydro-1H,5H-imidazo<4,5-e><1,3>diazepine-4,6-dione methyl5H,6H,7H,8H,9H-imidazo[1,2-a][1,4]diazepine-6-carboxylatedihydrochloride 3-(2,4-difluorophenyl)-7-(4-methoxybenzyl)-3,7-dihydro-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one 3-(3,5-dimethyl-cyclohexyl)-1-methyl-6-methylsulfanyl-1H-[1,3,5]triazine-2,4-dione 3-{5-[2-(2-Trimethylsilanyl-ethoxymethyl)-2H-tetrazol-5-yl]-pentyl}-3,6,7,8-tetrahydro-imidazo[4,5-d][1,3]diazepin-8-ol N-{4-[(8-cyclohexyl-2,8-diazaspiro[4.5]dec-2-yl)methyl]benzyl}-2-(1H-imidazol-4-yl)-N-(1H-imidazol-2-ylmethyl)ethanamine 4-Fluoro-3-[2-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester (8S)-3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-5-methylimidazo<4,5-d><1,3>diazepin-8-ol 6,7-dihydro-3-<<2-(p-toluoyloxy)ethoxy>methyl>imidazo<4,5-d><1,3>diazepin-8(3H)-one 3,4-dibenzyl-4,5,7,8-tetrahydro-6-hydroxy-6H-imidazo[4,5-e][1,4]diazepine-5,8-dione